<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04280536</url>
  </required_header>
  <id_info>
    <org_study_id>BR01/02/19</org_study_id>
    <nct_id>NCT04280536</nct_id>
  </id_info>
  <brief_title>Phase II Study of FTD/TPI (Lonsurf) in Metastatic Breast Cancers With or Without Prior Exposure to Fluoropyrimidines (LONBRECA)</brief_title>
  <official_title>Phase II Study of FTD/TPI (Lonsurf) in Metastatic Breast Cancers With or Without Prior Exposure to Fluoropyrimidines (LONBRECA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National University Hospital, Singapore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National University Hospital, Singapore</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single arm, open-label, lead in phase Ib dose confirmation, followed by phase II&#xD;
      study with 2 parallel study cohorts.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase Ib Patients will be treated with twice-daily dosing of FTD/TPI in a 3+3 dose escalation&#xD;
      design Phase II&#xD;
&#xD;
      Oral FTD/TPI at RP2D will be administered until disease progression, intolerable toxicity or&#xD;
      patient withdrawal.&#xD;
&#xD;
      2 parallel cohorts of patients will be enrolled : Cohort A : patients with prior exposure to&#xD;
      fluoropyrimidines Cohort B : patients without prior exposure to fluoropyrimidines&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 14, 2019</start_date>
  <completion_date type="Anticipated">October 2024</completion_date>
  <primary_completion_date type="Anticipated">October 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>2 parallel cohorts of patients will be enrolled : Cohort A : patients with prior exposure to fluoropyrimidines Cohort B : patients without prior exposure to fluoropyrimidines</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>4 months</time_frame>
    <description>Primary endpoint is proportion of patients who are PFS at 4 months in Cohort A</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response</measure>
    <time_frame>5 years</time_frame>
    <description>The death of any patient in the trial from any cause will be recorded and the amount of time from enrollment in the trial until death will be recorded in weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>6 months</time_frame>
    <description>Proportion of patients who are PFS at 6 months in Cohort B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Efficacy</measure>
    <time_frame>5 years</time_frame>
    <description>All adverse events experienced by all patients (in both cohort , RP2D of FTD/TPI in MBC Patients) exposed to Trifluridine/tipiracil will be recorded and graded according to CTCAE version 5.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">86</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with prior exposure to fluoropyrimidines</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients without prior exposure to fluoropyrimidines</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cohort A</intervention_name>
    <description>Oral FTD/TPI at RP2D will be administered until disease progression, intolerable toxicity or patient withdrawal.</description>
    <arm_group_label>Cohort A</arm_group_label>
    <other_name>trifluridine/tipiracil</other_name>
    <other_name>TAS-102 [Lonsurf]</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cohort B</intervention_name>
    <description>Oral FTD/TPI at RP2D will be administered until disease progression, intolerable toxicity or patient withdrawal.</description>
    <arm_group_label>Cohort B</arm_group_label>
    <other_name>trifluridine/tipiracil</other_name>
    <other_name>TAS-102 [Lonsurf]</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 21 years.&#xD;
&#xD;
          -  Histological or cytological diagnosis of breast carcinoma.&#xD;
&#xD;
          -  ECOG 0-2.&#xD;
&#xD;
          -  HER2 negative tumor (IHC 0 -1+ or IHC 2+ and confirmed on HER2 FISH to be negative&#xD;
             based on histological report).&#xD;
&#xD;
          -  Patients with HER2 positive tumor may be enrolled if they have failed at least two&#xD;
             lines of anti-HER2 based therapies in the metastatic setting, or are intolerant to&#xD;
             trastuzumab&#xD;
&#xD;
          -  Any hormone receptor status.&#xD;
&#xD;
          -  Any number of lines of prior palliative endocrine therapy for patients with hormone&#xD;
             receptor positive cancer.&#xD;
&#xD;
          -  Has measureable or evaluable disease based on RECIST 1.1 criteria&#xD;
&#xD;
          -  Estimated life expectancy of at least 12 weeks.&#xD;
&#xD;
          -  Has documented progressive disease from last line of therapy.&#xD;
&#xD;
          -  Has recovered from acute toxicities from prior anti-cancer therapies&#xD;
&#xD;
          -  Adequate organ function including the following:&#xD;
&#xD;
        oBone marrow: (I) Absolute neutrophil (segmented and bands) count (ANC) ≥1.5 x 109/L (ii)&#xD;
        Platelets ≥100 x 109/L (ii) Hemoglobin ≥8 x 109/L oHepatic: (I)Bilirubin ≤ 1.5 x upper&#xD;
        limit of normal (ULN), (ii)ALT or AST ≤ 2.5x ULN, (or ≤ 5 X with liver metastases) oRenal:&#xD;
        (I) Creatinine ≤1.5x ULN&#xD;
&#xD;
          -  Signed informed consent from patient or legal representative.&#xD;
&#xD;
          -  Able to comply with study-related procedures.&#xD;
&#xD;
          -  Prior therapy (patients enrolled in phase Ib may be enrolled if they fulfil prior&#xD;
             therapy criteria for either Cohort A or Cohort B)&#xD;
&#xD;
               -  Cohort A only: Has received at least 2 lines of palliative systemic therapy,&#xD;
                  including prior fluropyrimidines (capecitabine, TS-1 or 5-fluorouracil) in the&#xD;
                  palliative setting, or in the adjuvant setting; patients who have only prior&#xD;
                  exposure to adjuvant fluoropyrimidines must have relapsed within 12 months of&#xD;
                  completing adjuvant fluoropyrimidines&#xD;
&#xD;
               -  Cohort B only: Any number of prior lines of palliative chemotherapy and has not&#xD;
                  received fluoropyrimidines (capecitabine, TS-1 or 5-fluorouracil) in the&#xD;
                  palliative setting or in the adjuvant setting; patients who have prior exposure&#xD;
                  to adjuvant fluoropyrimidines are eligible if they have relapsed 12 months from&#xD;
                  completion of adjuvant fluoropyrimidines.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Treatment within the last 30 days with any investigational drug.&#xD;
&#xD;
          -  Concurrent administration of any other tumour therapy, including cytotoxic&#xD;
             chemotherapy, hormonal therapy, and immunotherapy.&#xD;
&#xD;
          -  Major surgery within 28 days of study drug administration.&#xD;
&#xD;
          -  Active infection that in the opinion of the investigator would compromise the&#xD;
             patient's ability to tolerate therapy.&#xD;
&#xD;
          -  Pregnancy.&#xD;
&#xD;
          -  Breast feeding.&#xD;
&#xD;
          -  Serious concomitant disorders that would compromise the safety of the patient or&#xD;
             compromise the patient's ability to complete the study, at the discretion of the&#xD;
             investigator.&#xD;
&#xD;
          -  Active bleeding disorder or bleeding site.&#xD;
&#xD;
          -  Non-healing wound.&#xD;
&#xD;
          -  Poorly controlled diabetes mellitus.&#xD;
&#xD;
          -  Second primary malignancy that is clinically detectable at the time of consideration&#xD;
             for study enrollment.&#xD;
&#xD;
          -  Symptomatic brain metastasis.&#xD;
&#xD;
          -  History of significant neurological or mental disorder, including seizures or&#xD;
             dementia.&#xD;
&#xD;
          -  Unable to comply with study procedures&#xD;
&#xD;
        Phase Ib lead-in can recruit patients who fulfil criteria for either Cohort A or Cohort B&#xD;
        AND all other inclusion/exclusion criteria&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Soo Chin Lee</last_name>
    <role>Principal Investigator</role>
    <affiliation>National University Hospital, Singapore</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Soo Chin Lee</last_name>
    <phone>6779 5555</phone>
    <email>soo_chin_lee@nuhs.edu.sg</email>
  </overall_contact>
  <location>
    <facility>
      <name>National University Hospital</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Soo Chin Lee</last_name>
      <phone>6779 5555</phone>
      <email>soo_chin_lee@nuhs.edu.sg</email>
    </contact>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <results_reference>
    <citation>Caswell-Jin JL, Plevritis SK, Tian L, Cadham CJ, Xu C, Stout NK, Sledge GW, Mandelblatt JS, Kurian AW. Change in Survival in Metastatic Breast Cancer with Treatment Advances: Meta-Analysis and Systematic Review. JNCI Cancer Spectr. 2018 Nov;2(4):pky062. doi: 10.1093/jncics/pky062. Epub 2018 Dec 24.</citation>
    <PMID>30627694</PMID>
  </results_reference>
  <results_reference>
    <citation>Crown J, Diéras V, Kaufmann M, von Minckwitz G, Kaye S, Leonard R, Marty M, Misset JL, Osterwalder B, Piccart M. Chemotherapy for metastatic breast cancer-report of a European expert panel. Lancet Oncol. 2002 Dec;3(12):719-27. Review.</citation>
    <PMID>12473512</PMID>
  </results_reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>February 10, 2020</study_first_submitted>
  <study_first_submitted_qc>February 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2020</study_first_posted>
  <last_update_submitted>August 11, 2020</last_update_submitted>
  <last_update_submitted_qc>August 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>FTD/TPI</keyword>
  <keyword>TAS-102</keyword>
  <keyword>Trifluridine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trifluridine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

